GLP1 receptor agonists (GLP1-RAs) are currently the most widely used pharmacological option to treat obesity. However, considerable heterogeneity in weight loss response has been observed with different anti-obesity drugs and response predictors to these drugs still remain ambiguous. Furthermore, very few published data have been available on cases of high-responders to treatment with GLP1-RAs. In this article, we present the case of a patient with grade 4 obesity (initial body mass index, 50.2kg/m2) with associated mechanical and metabolic complications who achieved an initial weight loss of 40% at 1 year with hygienic-dietary measures and drug treatment with liraglutide. We also review the available literature on factors potentially contributing to variations in weight loss with GLP1-RAs in general and liraglutide, in particular.
Keywords: Agonistas del receptor de GLP1 (AR-GLP1); GLP1 receptor agonists (GLP1-RAs); High-responders; Liraglutida; Liraglutide; Obesidad; Obesity; Súper-respondedores.
Copyright © 2024 SEEN and SED. Published by Elsevier España, S.L.U. All rights reserved.